BioAtla (BCAB) Common Equity (2020 - 2026)

BioAtla (BCAB) has reported Common Equity for 7 consecutive years, with -$36.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 116.4% year-over-year to -$36.2 million; the trailing twelve-month figure through Jun 2026 stood at -$36.2 million (down 116.4% YoY), and the FY2025 full-year result was -$36.2 million, down 353.69% from the prior year.
• Common Equity rose to -$36.2 million in Q2 2026 per BCAB's latest filing, from -$37.3 million in the prior quarter.
• Across five years, Common Equity topped out at $190.1 million in Q1 2022 and bottomed at -$37.3 million in Q1 2026.
• Historically, Common Equity has averaged $60.3 million across 5 years, with a median of $40.5 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Common Equity declined 2.99% in 2022, then slumped 6920.66% in 2026.
• Over 5 years, Common Equity stood at $180.3 million in 2022, then tumbled by 60.81% to $70.7 million in 2023, then sank by 79.82% to $14.3 million in 2024, then slumped by 353.69% to -$36.2 million in 2025, then fell by 0.13% to -$36.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$36.2 million, -$37.3 million, and -$36.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.